Under the agreement, Scriptr Global will conduct research, and Canbridge will be responsible for development, manufacturing, regulatory clearance, and marketing, it said. Financial terms of the agreement include an upfront payment, development and sales payments upon hitting certain milestones, as well as royalties based on net sales.

Dystrophinopathies are X-linked genetic muscular diseases such as Duchenne muscular dystrophy, Becker muscular dystrophy, and Duchenne muscular dystrophy-associated dilated cardiomyopathy, according to Canbridge.

Canbridge, UMass partner on gene therapies for neuromuscular diseases
Canbridge Pharmaceuticals has expanded its gene-therapy partnership with the University of Massachusetts (UMass) Medical School.